Biofrontera (BFRI) Projected to Post Quarterly Earnings on Thursday

Biofrontera (NASDAQ:BFRI) is anticipated to post its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Biofrontera to post earnings of ($0.1150) per share and revenue of $10.25 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 11:00 AM ET.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Thursday, March 19th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.29 by $0.21. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. The business had revenue of $17.10 million during the quarter, compared to analyst estimates of $16.15 million. On average, analysts expect Biofrontera to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biofrontera Stock Down 9.0%

BFRI stock opened at $1.01 on Wednesday. The stock has a market cap of $12.13 million, a PE ratio of -0.98 and a beta of 0.89. The firm’s 50-day simple moving average is $0.97 and its 200 day simple moving average is $0.90. Biofrontera has a fifty-two week low of $0.54 and a fifty-two week high of $1.19. The company has a quick ratio of 1.40, a current ratio of 1.52 and a debt-to-equity ratio of 0.44.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Biofrontera stock. Geode Capital Management LLC grew its holdings in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the period. Geode Capital Management LLC owned approximately 0.56% of Biofrontera worth $37,000 at the end of the most recent reporting period. Institutional investors own 10.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, April 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $2.75.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.